Abstract
B7-H3 (CD276), an orphan member of the B7 family, is an immune checkpoint ligand and a tumor-associated antigen. Recent developments regarding dimerization, glycosylation, expression regulation, and effects on cell metabolism are emerging, along with a newfound role as a regulator of obesity. As a therapeutic target, ongoing clinical trials with antibody-drug conjugates (ADCs) and chimeric antigen receptor (CAR) immune cells targeting B7-H3 have proved to be safe and effective across different human cancer types. Multiple new preclinical studies have also provided novel treatments targeting B7-H3, including TMIGD2 optimized potent/persistent (TOP) CAR cells, bispecific ADCs, CAR-natural killer (NK) cells, and T cell engagers. In this review we highlight the diverse emerging functions of B7-H3 in both physiological and pathological conditions, and discuss new therapies targeting this molecule.